Serum hepcidin / ferroportin levels in bipolar disorder and schizophrenia

Altun, İlkay Keleş; Atagün, Murat İlhan; Erdoğan, Ali; Yenilmez, Dicle; Yusifova, Aygün; Senat, Almila; Erel, Özcan

doi:10.1016/j.jtemb.2021.126843

Cited by 13 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies reported that Hepcidin levels were higher in Alzheimer's disease and attention deficit hyperactivity disorder (22,23) and Ferroportin levels were lower in schizophrenia patients (24). These results provide evidence to iron turn over especially the Hepcidin -Ferroportin axis, may be impaired in psychiatric disorders..…”

Section: Discussionmentioning

confidence: 60%

Iron transportation proteins Hepcidin and Ferroportin and alterations in depressive and anxiety disorders

Gürsoy¹,

Atagün²,

Üzer³

et al. 2022

Med Sci Discov

View full text Add to dashboard Cite

Objective: Iron element has critical roles such as myelin synthesis and neurotransmitter synthesis. Critical enzymes and proteins strictly control iron metabolism. Alterations in the enzyme activities could modify iron metabolism. Metabolic and endocrine changes may influence iron turnover in patients with major depression and anxiety disorders. Materials and Methods: 30 patients with major depressive disorder (MDD), 30 with anxiety disorders (ADs) according to the DSM 5 criteria, and 30 healthy controls were included. Hamilton Depression and Anxiety Scales were the clinical evaluation tools. Blood samples were collected 12 hours of fasting. Hepcidin and Ferroportin levels were measured with ELISA method. Results: Both Hepcidin and Ferroportin levels were lower in the MDD group compared to the ADs group, Hepcidin levels were found to be statistically significantly lower (p= 0.014). In addition, an inverse correlation was observed between the Hamilton Depression Scale score and Ferroportin levels (r= -0.214, p<0.05). Conclusion: Decreased Hepcidin and Ferroportin levels indicate metabolic effects in patients with MDD and disruption of the feedback mechanism between the two proteins. Considering the long duration of the disease in the MDD group in our study, the treatment period was also thought to be prolonged and the use of antidepressants might affect negative feedback.

show abstract

Section: Discussionmentioning

confidence: 60%

Iron transportation proteins Hepcidin and Ferroportin and alterations in depressive and anxiety disorders

Gürsoy¹,

Atagün²,

Üzer³

et al. 2022

Med Sci Discov

View full text Add to dashboard Cite

show abstract

“…Furthermore, ferritin levels were significantly lower in schizophrenic patients with (n = 30) and without (n = 30) akathisia compared to the control group (n = 30) (50) and also in bipolar manic patients compared to bipolar euthymic patients and to healthy controls. Still other studies found no significant differences in serum ferritin concentrations between patients with schizophrenia, bipolar disorder, anxiety, depression compared with controls (40,41,51).…”

Section: Introductionmentioning

confidence: 85%

“…We have examined whether serum ferritin differs based on survival (vs. mortality) and the presence (vs. absence) of psychiatric comorbidity Mean serum ferritin was markedly elevated in non-survivors (compared to survivors) without psychiatric comorbidity (922. 51…”

Section: The Effects Of Mortality and Delirium On Serum Ferritinmentioning

confidence: 99%

Attenuated initial serum ferritin concentration in critically ill coronavirus disease 2019 geriatric patients with comorbid psychiatric conditions

Abulseoud

Yehia²,

Egol³

et al. 2022

Front. Psychiatry

View full text Add to dashboard Cite

We examined the effects of psychiatric comorbidity, sex, and ICU admission on serum ferritin concentration in 628 elderly patients (79.7 ± 8.5 years) with positive SARS-CoV-2 PCR test. Hospitalization was required in 96% of patients and 17% required ICU admission. Patients with COVID-19 and psychiatric comorbidities (n = 212) compared to patients without psychiatric comorbidities (n = 416) had significantly lower ferritin concentration (570.4 ± 900.1 vs. 744.1 ± 965, P = 0.029), a greater incidence of delirium (22.6 vs. 14.4%, P = 0.013) and higher mortality (35.3 vs. 27.6%, P = 0.015). Furthermore, we found significant effects for sex (P = 0.002) and ICU admission (P = 0.007). Among patients without comorbid psychiatric conditions, males had significantly higher ferritin compared to females (1,098.3 ± 78.4 vs. 651.5 ± 94.4, P < 0.001). ICU patients without comorbid psychiatric conditions had significantly higher serum ferritin compared to ICU patients with comorbid psychiatric conditions: (1,126.6 ± 110.7 vs. 668.6 ± 156.5, P < 0.001). Our results suggest that the presence of comorbid psychiatric conditions in elderly patients with COVID-19 is associated with higher rates of delirium and mortality and lower ferritin levels during severe illness. Whether high serum ferritin is protective during severe infection requires further investigation.

show abstract

“…[15,16] LDH and ferritin, which are inflammation markers recently shown to predict the prognosis of COVID-19, may also be associated with the increased inflammatory response in these patients with BD. [17][18][19] In a study, it was also shown that serum LDH levels are higher in patients with BD than in patients with MDD. [19] In light of all this information, our study suggests that elevated LDH and ferritin values in patients with BD may be related to the increased response to COVID-19 in patients with BD.…”

Section: Discussionmentioning

confidence: 99%

The treatment of COVID-19 and severe mental illness together: comparing clinical features of patients with bipolar disorder and major depressive disorder

Tuna¹

2023

Comprehensive Med

View full text Add to dashboard Cite

Objective: COVID-19 can be codiagnosed in people who need to be treated in psychiatry services with symptoms such as acute mood or psychotic episodes, aggression, and suicidal thoughts. The aim of the study was to compare the clinical features of patients with COVID-19 and major depressive disorder (MDD) or bipolar disorder (BD). Materials and Methods:Of 84 patients, 60 were diagnosed with BD, and 24 were diagnosed with MDD. Patients, who were treated in a psychiatry service for COVID-19, were included in the study. The two groups were compared in terms of sociodemographic data, medications, psychiatric symptoms, comorbid diseases, progression (CALL) scores, laboratory markers of inflammation, and procoagulation.Results: There was no significant difference between the BD and MDD groups in terms of age and gender. While self-harm/suicidal ideation was found significantly more frequently in MDD patients compared to the BD group (p=0.024), agitation/aggression and treatment refusal rates were significantly higher in the BD group (p= 0.001, p= 0.002). Lactate dehydrogenase and ferritin levels were significantly higher in the BD group (p= 0.016, p= 0.032). Finally, there was no significant difference between the two groups in terms of CALL scores (p=0.678). Conclusion:Cases diagnosed with BD may need hospitalization for manic symptoms such as agitation/aggression/rejection of treatment during the pandemic period. BD may pose a susceptibility to inflammation associated with COVID-19 or given the underlying inflammation associated with illness. The treatment and primary prevention of these patients for COVID-19 may be of particular importance.

show abstract

Serum hepcidin / ferroportin levels in bipolar disorder and schizophrenia

Cited by 13 publications

References 34 publications

Iron transportation proteins Hepcidin and Ferroportin and alterations in depressive and anxiety disorders

Iron transportation proteins Hepcidin and Ferroportin and alterations in depressive and anxiety disorders

Attenuated initial serum ferritin concentration in critically ill coronavirus disease 2019 geriatric patients with comorbid psychiatric conditions

The treatment of COVID-19 and severe mental illness together: comparing clinical features of patients with bipolar disorder and major depressive disorder

Contact Info

Product

Resources

About